These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 27291307)

  • 1. Mucocutaneous toxicity induced by pegylated liposomal doxorubicin: a single-institution, retrospective case series.
    Vaccaro M; Santarpia M; Calapai G; Mannucci C; Borgia F; Altavilla G; Cannavò SP
    Br J Dermatol; 2017 Feb; 176(2):507-509. PubMed ID: 27291307
    [No Abstract]   [Full Text] [Related]  

  • 2. Intertrigo-like eruption caused by pegylated liposomal doxorubicin (PLD).
    Sánchez Henarejos P; Ros Martínez S; Marín Zafra GR; Alonso Romero JL; Navarrete Montoya A
    Clin Transl Oncol; 2009 Jul; 11(7):486-7. PubMed ID: 19574209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Striking follicular eruption to pegylated liposomal doxorubicin.
    Dai J; Micheletti R; Rosenbach M; Chu EY
    Am J Dermatopathol; 2014 Jul; 36(7):590-1. PubMed ID: 24614205
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "Skin problems associated with pegylated liposomal doxorubicin -- more than palmoplantar erythrodysesthesia syndrome".
    Von Moos R; Cathomas R
    Eur J Dermatol; 2009; 19(3):264-5. PubMed ID: 19213658
    [No Abstract]   [Full Text] [Related]  

  • 5. Pegylated liposomal doxorubicin in platinum-treated recurrent or metastatic cervical carcinoma.
    Ferrandina G; Lorusso D; Longo R; Testa AC; Scambia G
    Gynecol Oncol; 2005 Aug; 98(2):332-3. PubMed ID: 15907985
    [No Abstract]   [Full Text] [Related]  

  • 6. Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer.
    Tanyi JL; Smith JA; Ramos L; Parker CL; Munsell MF; Wolf JK
    Gynecol Oncol; 2009 Aug; 114(2):219-24. PubMed ID: 19446868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of palmar-plantar erythrodysesthesia in pretreated and unpretreated patients receiving pegylated liposomal doxorubicin.
    Miolo G; Baldo P; Bidoli E; Lombardi D; Scalone S; Sorio R; Veronesi A
    Tumori; 2009; 95(6):687-90. PubMed ID: 20210230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is the right way to administer pegylated liposomal doxorubicin in breast cancer therapy?
    Grenader T; Gabizon A
    J Clin Oncol; 2010 Apr; 28(12):e193-4; author reply e195-6. PubMed ID: 20194839
    [No Abstract]   [Full Text] [Related]  

  • 9. Absence of cardiotoxicity with prolonged treatment and large accumulating doses of pegylated liposomal doxorubicin.
    Blank N; Laskov I; Kessous R; Kogan L; Lau S; Sebag IA; Gotlieb WH; Rudski L
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):737-743. PubMed ID: 28801766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephrotic syndrome and acute renal failure during pegylated liposomal doxorubicin treatment.
    Carron PL; Padilla M; Maurizi Balzan J
    Hemodial Int; 2014 Oct; 18(4):846-7. PubMed ID: 25040096
    [No Abstract]   [Full Text] [Related]  

  • 11. Reduction in skin and mucosal toxicity with pegylated liposomal doxorubicin utilizing every 2-week dosing.
    Rose PG; Purpura D; Petersen L
    Anticancer Drugs; 2019 Jul; 30(6):636-639. PubMed ID: 30973518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiac safety profile of patients receiving high cumulative doses of pegylated-liposomal doxorubicin: use of left ventricular ejection fraction is of unproven value.
    Skubitz KM; Blaes AH; Konety SH; Francis GS
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):787-798. PubMed ID: 28856562
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1b study of trebananib in combination with pegylated liposomal doxorubicin or topotecan in women with recurrent platinum-resistant or partially platinum-sensitive ovarian cancer.
    Vergote I; Schilder RJ; Pippitt CH; Wong S; Gordon AN; Scudder S; Kridelka F; Dirix L; Leach JW; Ananda S; Nanayakkara N; Melara R; Bass MB; Litten J; Adewoye H; Wenham RM
    Gynecol Oncol; 2014 Oct; 135(1):25-33. PubMed ID: 25019569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term use of pegylated liposomal doxorubicin to a cumulative dose of 4600 mg/m2 in recurrent ovarian cancer.
    Pendlebury A; DeBernardo R; Rose PG
    Anticancer Drugs; 2017 Aug; 28(7):815-817. PubMed ID: 28542037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Absence of cutaneous complications following extravasation of pegylated liposomal doxorubicin].
    Capitain O; Lortholary A
    Presse Med; 2003 Jun; 32(23):1077. PubMed ID: 12910162
    [No Abstract]   [Full Text] [Related]  

  • 16. Plasmafiltration as a possible contributor to kinetic targeting of pegylated liposomal doxorubicin (PLD) in order to prevent organ toxicity and immunosuppression.
    Martínková J; Bláha M; Kubeček O; Maláková J; Špaček J; Bezouška J; Krulichová IS; Filip S
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):429-37. PubMed ID: 26678853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ["Hand-foot" syndrome--after liposomal pegylated doxorubicin in patients with the ovarian cancer recurrence (own experiences)].
    Mrochen-Domin I; Nowara E; Kaleta B
    Ginekol Pol; 2008 May; 79(5):332-7. PubMed ID: 18624107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity.
    Steppan I; Reimer D; Sevelda U; Ulmer H; Marth C; Zeimet AG
    Chemotherapy; 2009; 55(6):391-8. PubMed ID: 19955744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring long-term treatment with pegylated liposomal doxorubicin: how important is intensive cardiac follow-up?
    Grenader T; Goldberg A; Gabizon A
    Anticancer Drugs; 2010 Oct; 21(9):868-71. PubMed ID: 20679886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
    Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
    Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.